Quality Improvement Initiative in Immuno-Oncology (QI3)

The BMS Quality Improvement Initiative in Immuno-oncology (QI3) aims to support projects that improve the quality of care received by patients on I-O agents.

This year, the BMS QI3 aims to support quality improvement projects directed at transforming workflows to enhance the treatment experience for patients receiving subcutaneous immune checkpoint inhibitors. Project should focus on sustainable changes that optimize healthcare resource utilization and could have a broader impact across hospital centers (QI3-SC).

The BMS QI3-SC is open to all health care organizations in Canada. Healthcare professionals employed by or holding a position in a hospital, and actively involved in the delivery of health care to cancer patients treated with immune checkpoint inhibitors are eligible to apply on behalf of their Institution. The list of eligible professionals includes, but is not limited to:

• Physicians
• Pharmacists
• Nurses and all nursing-affiliated personnel
• Allied health professionals
• Other hospital-based professionals that participate in or who have an interest in improving the delivery of care to cancer patients treated with immune checkpoint inhibitors

Projects requesting up to 50,000ドル will be considered. Projects must have the potential to transfer knowledge and experience gained, to other disease sites, healthcare teams or hospitals.

Please refer to the Applicant Guide for additional details.

Applicants should download the QI3-SC Application Form and return the completed form to QI3@bms.com by August 15, 2025. Applications received after the deadline will not be reviewed.

Applicants will be notified of decisions by September 15, 2025.